Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics Limited has applied to the ASX for quotation of 33,212,500 new ordinary fully paid shares under the ticker NUZ. The securities were issued on 21 April 2026 as part of previously announced transactions, expanding the company’s quoted capital base and potentially improving liquidity for investors while supporting ongoing corporate and development activities.
The move formalises the admission of these newly issued shares to trading on the exchange and reflects the company’s continued use of equity markets to fund its operations. For shareholders and prospective investors, the enlarged free float may influence trading dynamics and capital-raising flexibility as Neurizon progresses its therapeutic programs.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.28 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company listed on the ASX under the code NUZ. The company operates in the therapeutics sector, focusing on the development of medical treatments, although specific lead products or therapeutic areas are not detailed in the filing.
YTD Price Performance: 4.71%
Average Trading Volume: 560,917
Technical Sentiment Signal: Sell
Current Market Cap: A$63.09M
Learn more about NUZ stock on TipRanks’ Stock Analysis page.